Javier de la Serna
- Hematology top 0.5%
- Genetics top 0.5%
- Molecular Biology top 10%
- Pathology and Forensic Medicine top 1%
- Immunology top 5%
- Co-authors
- Miguel Á. SanzMarcos GonzálezPau MontesinosJosé D. GonzálezSalut BrunetChelo RayónJuan BerguaGiuseppe Milone
- Topics
- Chronic Lymphocytic Leukemia Research (37 papers)Lymphoma Diagnosis and Treatment (33 papers)Acute Myeloid Leukemia Research (21 papers)
- Partner nations
- SpainUnited StatesItaly
In The Last Decade
Javier de la Serna
84 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 81
- Hematology 1.6k
- Genetics 1.2k
- Molecular Biology 1.1k
- Pathology and Forensic Medicine 953
- Immunology 492
Countries citing papers authored by Javier de la Serna
This map shows the geographic impact of Javier de la Serna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier de la Serna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier de la Serna more than expected).
Fields of papers citing papers by Javier de la Serna
This network shows the impact of papers produced by Javier de la Serna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier de la Serna. The network helps show where Javier de la Serna may publish in the future.
Co-authorship network of co-authors of Javier de la Serna
This figure shows the co-authorship network connecting the top 25 collaborators of Javier de la Serna. A scholar is included among the top collaborators of Javier de la Serna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier de la Serna. Javier de la Serna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 4 | |
| 4 | 0 | |
| 5 | 0 | |
| 6 | 1 | |
| 7 | 8 | |
| 8 | 15 | |
| 9 | ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemiabreakdown → | 252 |
| 10 | 1 | |
| 11 | 15 | |
| 12 | Ex Vivo Lymph Node Native Microenvironment Assay Shows Novel Antiproliferative Activity For Idelalisib And Ibrutinib On Cll Cells | 1 |
| 13 | 33 | |
| 14 | 3 | |
| 15 | 49 | |
| 16 | 26 | |
| 17 | 4 | |
| 18 | 37 | |
| 19 | 17 | |
| 20 | 24 |
About Javier de la Serna
Javier de la Serna is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 90 papers that have together received 2.8k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (33 papers) and Acute Myeloid Leukemia Research (21 papers). The work is most often cited by research in Hematology (1.6k citations), Genetics (1.2k citations) and Pathology and Forensic Medicine (953 citations). Javier de la Serna has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Miguel Á. Sanz, Marcos González, Pau Montesinos, José D. González, Salut Brunet, Chelo Rayón, Juan Bergua, Giuseppe Milone, Bob Löwenberg and Concha Rivas. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.